Key Takeaways
- Fourth-quarter revenue reached $9.7 billion, reflecting 9.9% year-over-year expansion — marking the company’s most robust annual sales growth in ten years
- Shares are valued at 13.5x forward earnings, below the historical 10-year mean of 16x and trailing competitors including Abbott and Stryker
- Cardiac Ablation Solutions division posted 78% global revenue growth and 124% expansion in the United States, capturing significant territory from Boston Scientific
- Hugo robotic surgical platform carries a price tag approximately 40% lower than Intuitive Surgical’s da Vinci, positioning it in a market forecast to surpass $54 billion
- Wall Street firms TD Cowen and RBC Capital Markets maintain price objectives of $119 and $118 respectively, suggesting more than 50% appreciation potential
Medtronic (MDT) shares have endured a challenging period in recent years. The medical technology powerhouse developed a track record of underdelivering against expectations, with its stock price bearing the consequences. However, recent developments signal a potential turning point.
The corporation’s fourth-quarter fiscal 2026 earnings release on June 3 exceeded Wall Street projections. Sales climbed 9.9% compared to the prior year, reaching $9.7 billion. This momentum drove full-year expansion to 8.4% — representing the strongest annual revenue performance in a full decade.
MDT shares currently hover near $78, well below their 52-week peak of $106.33. With a forward earnings multiple of 13.5 and a dividend yield of 3.7%, the valuation appears attractive when measured against historical norms and industry competitors.
The company’s 10-year average forward price-to-earnings ratio stands near 16. Industry rivals such as Abbott, Boston Scientific, Johnson & Johnson, and Stryker command price-to-sales ratios around 4. Medtronic’s comparable metric rests at 2.8.
Shagun Singh, analyst at RBC Capital Markets, maintains an Outperform recommendation with a $118 price objective. TD Cowen reaffirmed its Buy stance with a $119 target. The consensus centers on one theme: Medtronic stands at the front end of a substantial product innovation wave.
Cardiac Ablation Technology Powers Performance
The cardiovascular division represents the brightest spot in the portfolio. This segment accounts for approximately 39% of consolidated revenue and expanded 10% year-over-year to $3.8 billion in the most recent quarter.
Within this category, Cardiac Ablation Solutions (CAS) demonstrates exceptional momentum. Revenue surged 78% on a global basis and an impressive 124% across U.S. markets. The franchise is expanding at double the underlying market rate while capturing eight percentage points of additional market penetration.
This incremental share is being extracted primarily from Boston Scientific, which acknowledged PFA market share losses as a contributing factor to its reduced full-year guidance. Boston Scientific equity has declined 51% year to date.
Medtronic’s competitive advantage stems from its position as the sole manufacturer with dual FDA-approved pulsed field ablation platforms: PulseSelect and the Affera System. Affera uniquely integrates PFA and radio-frequency energy alongside comprehensive cardiac mapping capabilities. CEO Geoff Martha noted that the U.S. installed base expanded 40% on a sequential basis during the last quarter.
Hugo Robotics and the Surgical Technology Frontier
Beyond cardiac solutions, Medtronic’s Hugo robotic-assisted surgical platform represents a compelling long-term growth vector within the company’s portfolio.
Hugo secured FDA authorization for urological procedures in 2025. Regulatory submissions for general surgery and gynecological applications are currently under review. The system’s pricing structure sits roughly 40% beneath Intuitive Surgical’s da Vinci platform.
Robotic-assisted procedures currently represent less than 5% of total surgical volume globally. Industry projections indicate the worldwide market will expand beyond $54 billion throughout the coming decade.
In the neuroscience division, fourth-quarter sales increased 5%. Medtronic also obtained FDA clearance during the current year for an innovative Stealth AXiS Spine application designed for brain surgery procedures, broadening its AiBLE surgical technology platform.
Regarding renal care, Needham reaffirmed a Buy rating and $101 price target this week, highlighting Symplicity Spyral sales running at an annualized $100 million pace. Medicare reimbursement commenced in October 2025.
Looking toward fiscal 2027, Medtronic projects organic revenue expansion between 6.75% and 7.25% with adjusted earnings per share ranging from $5.90 to $6.00, representing approximately 8% growth from the prior year’s $5.53.
The organization has increased its dividend distribution for 49 consecutive years. The present quarterly dividend stands at $0.72 per share.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
